500124:BOM
Dr Reddy's Laboratories Ltd
1.239,65 ₹
arrow_upward
+0,74%(+9,15) 1d
13 d’oct., 15:50:20 GMT+5:30 · INR
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a 500124...
Obre
1.228,15 ₹
Alt
1.250,95 ₹
Baix
1.223,80 ₹
Capitalització borsària
1,03 B
Volum mitjà
84,13 k
Volum
125,77 k
Dividend
0,65 %
Dividend trimestral
2,00 ₹
Data de l'exdividend
10 de jul. 2026
Ràtio preu-benefici
32,06
Alt 52 setmanes
1.414,40 ₹
Baix 52 setmanes
1.080,05 ₹
BPA
38,67 ₹
Accions en circulació
166,06 M
Nombre d'empleats
28 k
Obre
1.228,15 ₹
Alt
1.250,95 ₹
Baix
1.223,80 ₹
Capitalització borsària
1,03 B
Volum mitjà
84,13 k
Volum
125,77 k
Dividend
0,65 %
Dividend trimestral
2,00 ₹
Data de l'exdividend
10 de jul. 2026
Ràtio preu-benefici
32,06
Alt 52 setmanes
1.414,40 ₹
Baix 52 setmanes
1.080,05 ₹
BPA
38,67 ₹
Accions en circulació
166,06 M
Nombre d'empleats
28 k
Notícies
De fonts web i partners de notícies
www.marketscreener.com
·
fa 21 hores
Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
Perfil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Sobre Dr Reddy's Laboratories Ltd
Conseller delegatErez Israeli
Empleats27,5 k
Fundació1984
Seu principalHyderabad, Andhra Pradesh, Índia
Sector-
Lloc webdrreddys.com